SymbolCRDF
NameCARDIFF ONCOLOGY, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address11055 FLINTKOTE AVENUE, SAN DIEGO, California, 92121, United States
Telephone+1 858 952-7570
Fax
Email
Websitehttps://www.cardiffoncology.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001213037
Description

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Additional info from NASDAQ:
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

2026-04-28 22:13

Aggarwal Ajay 🟢 acquired 400.0K shares (1 derivative) of Cardiff Oncology, Inc. (CRDF) at $1.72 Transaction Date: Apr 27, 2026 | Filing ID: 000004

Read more
2026-04-28 20:01

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-04-28 19:11

New Form 3 - Cardiff Oncology, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0002132312-26-000003 <b>Size:</b> 3 KB

Read more
2026-04-23 17:46

New Form DEFA14A - Cardiff Oncology, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001213037-26-000007 <b>Size:</b> 429 KB

Read more
2026-04-23 17:45

New Form DEF 14A - Cardiff Oncology, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001213037-26-000006 <b>Size:</b> 2 MB

Read more
2026-04-23 17:41

New Form ARS - Cardiff Oncology, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001213037-26-000004 <b>Size:</b> 955 KB

Read more
2026-04-21 14:00

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Read more
2026-04-17 20:01

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Read more
2026-04-16 21:08

New Form 3 - Cardiff Oncology, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001651911-26-000008 <b>Size:</b> 3 KB

Read more
2026-04-16 21:07

New Form 4/A - Cardiff Oncology, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001651911-26-000006 <b>Size:</b> 5 KB

Read more